These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16246623)

  • 1. DNA microarray genotyping of N-acetyltransferase 2 polymorphism using carbodiimide as the linker for assessment of isoniazid hepatotoxicity.
    Shimizu Y; Dobashi K; Mita Y; Endou K; Moriya S; Osano K; Koike Y; Higuchi S; Yabe S; Utsugi M; Ishizuka T; Hisada T; Nakazawa T; Mori M
    Tuberculosis (Edinb); 2006 Sep; 86(5):374-81. PubMed ID: 16246623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity.
    Ohno M; Yamaguchi I; Yamamoto I; Fukuda T; Yokota S; Maekura R; Ito M; Yamamoto Y; Ogura T; Maeda K; Komuta K; Igarashi T; Azuma J
    Int J Tuberc Lung Dis; 2000 Mar; 4(3):256-61. PubMed ID: 10751073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
    Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
    Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis.
    Vuilleumier N; Rossier MF; Chiappe A; Degoumois F; Dayer P; Mermillod B; Nicod L; Desmeules J; Hochstrasser D
    Eur J Clin Pharmacol; 2006 Jun; 62(6):423-9. PubMed ID: 16770646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.
    Azuma J; Ohno M; Kubota R; Yokota S; Nagai T; Tsuyuguchi K; Okuda Y; Takashima T; Kamimura S; Fujio Y; Kawase I;
    Eur J Clin Pharmacol; 2013 May; 69(5):1091-101. PubMed ID: 23150149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis.
    Cho HJ; Koh WJ; Ryu YJ; Ki CS; Nam MH; Kim JW; Lee SY
    Tuberculosis (Edinb); 2007 Nov; 87(6):551-6. PubMed ID: 17950035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.
    Huang YS; Chern HD; Su WJ; Wu JC; Lai SL; Yang SY; Chang FY; Lee SD
    Hepatology; 2002 Apr; 35(4):883-9. PubMed ID: 11915035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India.
    Gupta VH; Amarapurkar DN; Singh M; Sasi P; Joshi JM; Baijal R; Ramegowda PH; Amarapurkar AD; Joshi K; Wangikar PP
    J Gastroenterol Hepatol; 2013 Aug; 28(8):1368-74. PubMed ID: 23875638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis.
    Higuchi N; Tahara N; Yanagihara K; Fukushima K; Suyama N; Inoue Y; Miyazaki Y; Kobayashi T; Yoshiura K; Niikawa N; Wen CY; Isomoto H; Shikuwa S; Omagari K; Mizuta Y; Kohno S; Tsukamoto K
    World J Gastroenterol; 2007 Dec; 13(45):6003-8. PubMed ID: 18023090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NAT2 Genotypes in Moroccan Patients with Hepatotoxicity Due to Antituberculosis Drugs.
    Guaoua S; Ratbi I; El Bouazzi O; Hammi S; Tebaa A; Bourkadi JE; Bencheikh RS; Sefiani A
    Genet Test Mol Biomarkers; 2016 Nov; 20(11):680-684. PubMed ID: 27541622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic association between
    Khan S; Mandal RK; Elasbali AM; Dar SA; Jawed A; Wahid M; Mahto H; Lohani M; Mishra BN; Akhter N; Rabaan AA; Haque S
    Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30509962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1.
    Xiang Y; Ma L; Wu W; Liu W; Li Y; Zhu X; Wang Q; Ma J; Cao M; Wang Q; Yao X; Yang L; Wubuli A; Merle C; Milligan P; Mao Y; Gu J; Xin X
    PLoS One; 2014; 9(1):e85905. PubMed ID: 24465778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis.
    Shi J; Xie M; Wang J; Xu Y; Liu X
    Pharmacogenomics; 2015 Dec; 16(18):2083-97. PubMed ID: 26616266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients.
    Wattanapokayakit S; Mushiroda T; Yanai H; Wichukchinda N; Chuchottawon C; Nedsuwan S; Rojanawiwat A; Denjanta S; Kantima T; Wongyai J; Suwankesawong W; Rungapiromnan W; Kidkeukarun R; Bamrungram W; Chaiwong A; Suvichapanich S; Mahasirimongkol S; Tokunaga K
    Int J Tuberc Lung Dis; 2016 Oct; 20(10):1364-1369. PubMed ID: 27725049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of N-acetyltransferase 2 genotype with isoniazid acetylation in Polish tuberculosis patients.
    Zabost A; Brzezińska S; Kozińska M; Błachnio M; Jagodziński J; Zwolska Z; Augustynowicz-Kopeć E
    Biomed Res Int; 2013; 2013():853602. PubMed ID: 24383060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case series of three patients presenting with isoniazid induced toxicity and N-acetyl transferase 2 gene mutation: A management conundrum for programmatic therapy of tuberculosis in India.
    Shetty P; Panchal F; Munshi R; Sundar U; Darole P
    Indian J Tuberc; 2020 Jul; 67(3):407-410. PubMed ID: 32825881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution of allelic and genotypic frequencies of NAT2 and CYP2E1 variants in Moroccan population.
    Guaoua S; Ratbi I; Laarabi FZ; Elalaoui SC; Jaouad IC; Barkat A; Sefiani A
    BMC Genet; 2014 Dec; 15():156. PubMed ID: 25544508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients.
    Santos NP; Callegari-Jacques SM; Ribeiro Dos Santos AK; Silva CA; Vallinoto AC; Fernandes DC; de Carvalho DC; Santos SE; Hutz MH
    Int J Tuberc Lung Dis; 2013 Apr; 17(4):499-504. PubMed ID: 23394127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients.
    An HR; Wu XQ; Wang ZY; Zhang JX; Liang Y
    Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):535-43. PubMed ID: 22506592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients.
    Ben Fredj N; Gam R; Kerkni E; Chaabane A; Chadly Z; Boughattas N; Aouam K
    Pharmacogenomics J; 2017 Jul; 17(4):372-377. PubMed ID: 27089936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.